Hot
Human GUCY2C / Guanylyl cyclase C Protein, Fc Tag, low endotoxin (MALS verified)Cat. No. GUC-H5257
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| Anti-GCC humanized antibody | Bispecific antibody | Oncology/Cancer | Solid Tumor | Preclinical | Global |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| anti-GUCY2C CAR T-cell therapy (Parasol Biotechnology/Anhui provincial cancer hospital) | Phase 1 Clinical | HeFei Parasol Biotech Co Ltd | Colorectal Neoplasms | Details | |
| anti-guanylyl cyclase C CAR-T cell therapy (Legend Biotech) | LCAR-G08T | Phase 1 Clinical | Legend Biotech Corp | Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
| HD-006 | HD006; HD-006 | Phase 1 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Solid tumours | Details |
| REVO-UWD-01 | REVO-UWD-01; WD 01 | Phase 1 Clinical | Wondercel Therapeutics Co Ltd | Colorectal Neoplasms | Details |
| IM96 CAR-T cell Therapy | IM96 | Phase 1 Clinical | Imunopharm Technology Co Ltd | Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| GCC19CART | GCC19CART; LYL273; LYL-273 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Colorectal Neoplasms; Rectal Neoplasms | Details |
| Gucy2c cart cell therapy (Innovative Cellular Therapeutics) | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Digestive System Neoplasms | Details | |
| XKDCT-080 | XKDCT-080 | Clinical | The Affiliated Hospital Of Qingdao University | Colonic Neoplasms; Solid tumours | Details |
| CT-080 | CT-080 | Clinical | Shenzhen Celconta Life Science Co Ltd | Solid tumours | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Plecanatide | SP-304; GCRA | Approved | Synergy Pharmaceuticals Inc | Trulance | United States | Constipation; Chronic idiopathic constipation | Salix Pharmaceuticals | 2017-01-19 | Chronic idiopathic constipation; Constipation; Irritable Bowel Syndrome | Details |